Simulation of clinical trials: concepts and basic principles

Abstract

Abstract: This paper reviewed the development, design and applications of clinical trial simulation (CTS).It introduced the clinical trial simulation from the view of the pharmacokinetics and pharmacodynamics. Then the general techniques, computer models and simulation software used for CTS were analyzed. Finally, some applications of clinical trial simulation were discussed.

Key words: clinical trial, computer simulation, simulation model, pharmacokinetics, pharmacodynamics

CLC Number:

R969

ZHENG Dan, ZHU Ling, SHI Xin-ling, ZHANG Yu-feng. Simulation of clinical trials: concepts and basic principles[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(6): 705-709.

References

1 Leahy DE.Drug discovery information integration: virtual humans for pharmacokinetics[J]. DDT:BIOSILICO, 2004; 2: 78-84.
2 Kraiczi H, Frisen M.Effect of uncertainty about population parameters on pharmacodynamics-based prediction of clinical trial power[J]. Contemp Clin Trials, 2005;26: 118-130.
3 Maxwell C, Domenet JG, Joyce CRR.Instant experience in clinical trials:a novel aid to teaching by simulation[J]. Clin Pharmacol, 1971; 11:323-331.
4 Holford NH, Kimko HC, Monteleone JP, et al. Simulation of clinical trials [J]. Annu Rev Pharmacol Toxicol, 2000;40:209-234.
5 黄晓晖, 史军, 李俊, 等.药代动力学和药效动力学中数学建模与模拟的基本原理(1)[J]. 中国临床药理学与治疗学, 2007; 1:88-95.
6 Chaikin P, Rhodes GR, Bruno R, et al. Pharmacokinetics/pharmacodynamics in drug development:an industrial perspective [J]. J Clin Pharmacol, 2000;40:1428-1438.
7 Derendorf H, Meibohm B.Modeling of pharmacokinetic/pharmacodynamic (PK/PD)relationships:concepts and perspectives [J]. Pharm Res, 1999; 16:176-185.
8 Derendorf H, Lesko LJ, Chaikin P, et al. Pharmacokinetic/pharmacodynamic modeling in drug research and development [J]. Clin Pharmacol, 2000; 40:1399-1418.
9 Chabaud S, Girard P, Nony P, et al. Clinical trial simulation using therapeutic effect modeling: application to ivabradine efficacy in patients with angina pectoris[J]. J Pharmacokinet Pharmacodyn, 2002; 29:339-363.
10 Reigner BG, Williams PE, Patel IH, et al. An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche[J]. Clin Pharmacokinet, 1997;33: 142-152.
11 Blesch KS, Gieschke R, Tsukamoto Y, et al. Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience[J]. Invest New Drugs, 2003;21: 195-223.
12 Aarons L, Karlsson MO, Mentre F, et al. Role of modelling and simulation in Phase Ⅰ drug development[J]. Eur J Pharm Sci, 2001;13: 115-122.
13 Isterm PF, Martin NE, Haskell LP, et al. Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240[J]. J Clin Pharmacol, 2004; 44:621-631.
14 Kowalski KG, Hutmacher MM.Design evaluation for a population pharmacokinetic study using clinical trial simulations: a case study[J]. Stat Med, 2001;20: 75-91.
15 Kimko HC, Dufful SB.Simulation for designing clinical trials [M]. 1st ed.New York:Marcel Dekker Inc, 2003:271-288.
16 Duffull SB, Chabaud S, Nony P, et al. A pharmacokinetic simulation model for ivabradine in healthy volunteers[J]. Eur J Pharm Sci, 2000;10: 285-294.

[1]	WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
[2]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[3]	WANG Anjing, WANG Yaya, LIANG Xuan, YAN Yajie, SU Jing, LI Caidong. Research progress on mechanisms and therapeutic drugs of peroxisome proliferator-activated receptor in treatment of cholestatic liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 796-808.
[4]	HE Xueru, LI Ying, MA Yinling, FU Yuhao, XUN Xuejiao, DONG Zhanjun. Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 498-507.
[5]	HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.
[6]	LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
[7]	YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei. Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177.
[8]	WANG Zhi, ZHOU Xin, HE Xueru, FU Yuhao, XUN Xuejiao, LI Ying, DONG Zhanjun. Clinical research progress of palbociclib in treatment of breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 205-213.
[9]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[10]	ZHOU Jiating, ZHANG Xuan, XIE Zilan, LI Zhi. Interactions and clinical significance of gut microbiota and levothyroxine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1307-1314.
[11]	LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
[12]	WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan. Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145.
[13]	DAI Jiahui, SUN Sijia, XIE Xuefeng. Quality management and indicator system for clinical trials of medical devices [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 51-58.
[14]	MA Shen, LIU Yushuo, TANG Hui, CHEN Wenbin, GAO Ling. Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 908-918.
[15]	CHEN Jianfang, LOU Donghua. Design of case report form for oncology clinical trials based on CDASH [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 762-767.